Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(E/Z)-TG003 是一种有效的 ATP 竞争性 Cdc2 样激酶 (Clk) 抑制剂,抑制 Clk1 和 Clk4 的 IC50值分别为 20 和 15 nM。它是 (Z)-TG003 和 (E)-TG003的消旋体。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 253 | 现货 | ||
2 mg | ¥ 356 | 现货 | ||
5 mg | ¥ 668 | 现货 | ||
10 mg | ¥ 1,050 | 现货 | ||
25 mg | ¥ 1,980 | 现货 | ||
50 mg | ¥ 3,630 | 现货 | ||
100 mg | ¥ 5,230 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 693 | 现货 |
产品描述 | (E/Z)-TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor. |
靶点活性 | CLK2 (mouse):200 nM, CLK1 (mouse):20 nM, CLK4 (mouse):15 nM |
体外活性 | 10 μM TG003能够治疗非洲爪蟾体内过度Clk活性诱导的胚胎缺陷. |
体内活性 | TG003通过抑制IL-1β异核RNA的剪接阻断血小板产生IL-1β RNA。在3T3-L1脂肪细胞分化过程中,TG003也阻断PKCβII的可变剪接和PPARγ1和PPARγ2的表达。TG003通过抑制Clk1/Sty介导的磷酸化抑制人类β珠蛋白在体外的SF2/ASF依赖性剪接。TG003抑制哺乳动物细胞中Clk1/Sty激酶活性,而对10 μM浓度的HeLa和COS-7细胞的生长没有毒性作用。 |
激酶实验 | In Vitro Kinase Assay : Kinase activity of Clks and SRPKs is assayed in a reaction mixture, containing 200 mM Tris-HCl (pH 7.5), 12.5 mM MgCl2, 8 mM dithiothreitol, 4 mM EGTA, 1–20 μM ATP, 1 μCi of [γ-32P]ATP, 1 μg of synthetic peptide of SF2/ASF RS domain (NH2-RSPSYGRSRSRSRSRSRSRSRSNSRSRSY-OH), and 0.1–1 μg of purified kinases in a final volume of 40 μL. cAMP-dependent protein kinase activity is assayed in a reaction mixture containing 80 mM Tris-HCl (pH 7.5), 12.5 mM MgCl2, 8 mM dithiothreitol, 4 mM EGTA, 10 μM ATP, 1 μCi of [γ-32P]ATP, 5 μg of histone H1, and 1 μg of catalytic subunit of rat cAMP-dependent protein kinase purified. Protein kinase C activity is assayed in a reaction mixture containing 200 mM Tris-HCl (pH 7.5), 12.5 mM MgCl2, 1 mM CaCl2, 80 μg/mL phosphatidylserine, 8 μg/mL diolein, 10 μM ATP, 1 μCi of [γ-32P]ATP, 5 μg of histone H1, and 2 μL of partially purified rat protein kinase C. The final concentration of Me2SO is adjusted to 1% regardless of inhibitor concentration. The reaction mixture is incubated at 30 or 25 °C for mammalian or Xenopus recombinant proteins, respectively, for 10 min, and a half-portion is spotted on P81 phosphocellulose membrane. The kinase assay conditions, including the incubation period and concentration of kinases and substrates, are optimized to maintain the linearity during incubation. The membrane is washed with 5% phosphoric acid solution (SF2/ASF RS domain) or 5% trichloroacetic solution (histone H1) at least over 15 min. The radioactivity is measured using a liquid scintillation counter. The net radioactivity is deduced by subtracting the background count from the reaction mixture without kinase, and the data are expressed as the percentage to the control sample containing the solvent. |
细胞实验 | 2 × 105 HeLa cells or 1.5 × 105 COS-7 cells resuspended in 2 mL of medium are plated on 6-well dishes, and 2 μL of 10 mM TG003 dissolved in Me2SO (final concentration at 10 μM), or 2 μL of Me2SO, is added to some wells. Cells are trypsinized, and the density is counted every 24 h for 3 days. Cells are then fixed with 1 mL of ice-cold 70% ethanol, washed with PBS, incubated in 1 ml of PBS containing 1 μg/mL DNase-free RNase A and 50 μg/mL propidium iodide for 20 min at 37 °C, and proceeded to cell cycle analysis by FACSCalibur.(Only for Reference) |
别名 | TG003 |
分子量 | 249.33 |
分子式 | C13H15NO2S |
CAS No. | 300801-52-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6 mg/mL (24.06 mM), Heating is recommended.
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.0107 mL | 20.0537 mL | 40.1075 mL | 100.2687 mL |
5 mM | 0.8021 mL | 4.0107 mL | 8.0215 mL | 20.0537 mL | |
10 mM | 0.4011 mL | 2.0054 mL | 4.0107 mL | 10.0269 mL | |
20 mM | 0.2005 mL | 1.0027 mL | 2.0054 mL | 5.0134 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(E/Z)-TG003 300801-52-9 Apoptosis Cell Cycle/Checkpoint BCL CDK (E/Z) TG003 Cyclin dependent kinase (E/Z)-TG-003 site TG003 tumor Wilm's TG-003 splice inhibit mutation Inhibitor TG 003 cancer (E/Z)TG003 (E/Z)-TG 003 breast inhibitor